Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study

Journal of Medical Economics

Volumn 14, Issue 3, 2011, Pages 350-356

  Li, Shu Chuen ^a   Aggarwal, Sanjay Kumar ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Sanofi aventis   (Singapore)

Author keywords

Bipolar I disorder; Cost effectiveness; Lithium; VALID study; Valproate

Indexed keywords

LITHIUM; VALPROIC ACID;

ABSENTEEISM; ADULT; AGED; ARTICLE; BIPOLAR I DISORDER; COST BENEFIT ANALYSIS; COST CONTROL; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OPEN STUDY; OUTPATIENT CARE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SOCIAL ASPECT;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COST-BENEFIT ANALYSIS; FEMALE; HEALTH SERVICES; HUMANS; LITHIUM; MALE; MULTICENTER STUDIES AS TOPIC; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALPROIC ACID;

EID: 79956131463     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.581321     Document Type: Article

References (30)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-52 (Pubitemid 46718287)
2. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:213-19
3. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19:483-95 (Pubitemid 32488750)
4. Bryan-Comstock L, Stender M, Devercelli G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disorder 2002;4:398-405 (Pubitemid 36041470)
5. Keck Jr PE, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 1996;57:213-22 (Pubitemid 26158857)
6. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4):1-50
7. Goodwin GM. Evidence-based guidelines for treating bipolar disorder recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17,149-73 (Pubitemid 36753531)
8. Yatham LN, Kennedy SH, O'Donovan C, et al; Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006;8:721-39 (Pubitemid 44824712)
9. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 2003;4:5-13
10. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9 (Pubitemid 30257262)
11. Bowden C, Göǧüş A, Grunze H, et al. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol 2008;23:254-62
12. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148-55 (Pubitemid 36084060)
13. Bowden CL, Mosolov S, Hranov L, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol 2010;25:60-7
14. Keck Jr PE, McElroy EL, Bennett JA. Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry 1996;57(13), 13-18 (Pubitemid 26427816)
15. Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005;23:583-94 (Pubitemid 40994126)
16. Dalkilic A, Diaz E, Baker CB, et al. Effects of divalproex versus lithium on length of hospital stay among patients with bipolar disorder. Psychiatr Serv 2000;51:1184-6
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (4th edn) Text Revision. Washington DC: American Psychiatric Association, 2000
18. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35 (Pubitemid 9006756)
19. World Medical Association. Declaration of Helsinki, 3rd (Hong Kong) amendment, 1989
20. European Medicines Agency. ICH Topic E 6 (R1) Guideline for Good Clinical Practice. CPMP/ICH/135/95, 2002
21. Central Intelligence Agency. The World Factbook. Available at: https://www.cia.gov/library/publications/the-world-factbook/index.html. Accessed: December 5, 2009
22. Australian Government Department of Health and Aging. MBS Online: Medicare Benefits Schedule. Available at: http://www.health.gov.au/internet/ mbsonline/publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1 Accessed: December 5, 2009
23. Australian Government Department of Health and Aging. Australian Refined Diagnosis Related Groups (AR-DRGs). Available at: http://www.health.gov.au/ internet/main/publishing.nsf/Content/health-casemix-ardrg1.htm. Accessed: April 1, 2010
24. Universal Currency Converter. Available at: http://www.xe.com/ucc/ convert.cgi Accessed: November 13, 2007
25. Australian Bureau of Statistics. Employee earnings and hours. 6306.0. Available at: http://www.ausstats.abs.gov.au/Ausstats/subscriber.nsf/0/ 284EA51F2E7BD8F9CA25728F000D10AC/$File/63060-May%202006.pdf Updated: March 8, 2007. Accessed December 5, 2009
26. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorders. Lancet 2002;359:241-6
27. Fountoulakis KN, Vieta E, Sanchez-Moreno J, et al. Treatment guidelines for bipolar disorder: A critical review. J Affect Disord 86;2005:1-10 (Pubitemid 40487954)
28. Revicki DA, Hirschfield RMA, Ahearn EP, et al. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorders: results of a naturalistic clinical trial. J Affect Disord 2005;86:183-93 (Pubitemid 40780031)
29. Svarstad BL, Shireman TI, Sweeny JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-11 (Pubitemid 32577440)
30. Health Care Consultants of America, Inc. Physicians Fee and Coding Guide: A Comprehensive Fee and Coding Reference. Augusta, GA: MAG Mutual Group, 1997